Supreme Court to Review Patent Settlements on Generic Drugs

The U.S. Supreme Court agreed to consider the legality of patent settlements in which pharmaceutical companies that sell branded drugs pay generic-drug makers to delay the sale of their versions.

The issue is a top priority for the Federal Trade Commission, which for several years has waged a campaign against patent deals that can postpone the sale of generic drugs. The FTC says the settlements deprive the public of billions of...